Lexotan

Package leaflet: Information for the patient

Warning! Please keep this leaflet. The information on the immediate packaging is in a foreign language.
Lexotan (Lexotanil), 3 mg, tablets
Bromazepamum
Lexotan and Lexotanil are different brand names of the same medicinal product.
Please read this leaflet carefully before taking this medicine, as it contains
important information for the patient.

• Please keep this leaflet so that you can read it again if necessary.
• If you have any doubts, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not give it to others. This medicine may harm another person, even if their symptoms are the same.
• If you experience any adverse effects, including any not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.

Table of contents

1. What Lexotan is and what it is used for
2. What you need to know before taking Lexotan
3. How to take Lexotan
4. Possible side effects
5. How to store Lexotan
6. Contents of the pack and other information

1. What Lexotan is and what it is used for

Lexotan contains bromazepam, which is an anxiolytic medicine belonging to the benzodiazepine group.
Lexotan is indicated for pharmacological treatment of:

• generalized anxiety disorders
• autonomic dysfunctions presenting somatically, including skin symptoms, gastrointestinal, cardiovascular, and urogenital system symptoms
• anxiety states occurring in the course of chronic organic diseases of the central nervous system
• post-traumatic stress disorders with anxiety symptoms
• adjustment disorders.

2. Important information before using Lexotan

When not to use Lexotan

• if the patient is allergic to benzodiazepines or to any of the other ingredients of this medicine (listed in section 6)
• if the patient has severe respiratory insufficiency
• if the patient has severe hepatic insufficiency (benzodiazepines are not indicated for treatment of patients with severe liver impairment due to the risk of brain damage)
• if the patient has muscle weakness (myasthenia gravis)
• if the patient has sleep apnoea syndrome.

Warnings and precautions

The patient should remain under medical supervision throughout the duration of treatment – initially, to establish the minimum effective dose and dosing frequency, and during treatment to prevent overdose.

Memory impairment

Benzodiazepines may cause anterograde amnesia. This condition most commonly occurs several hours after taking the medicine. To reduce the risk of anterograde amnesia, the patient should have uninterrupted sleep for several hours. Anterograde amnesia may be associated with abnormal behaviour.

Psychological reactions

When using benzodiazepines, reactions such as anxiety, agitation, irritability, aggression, anxiety, delusions regarding the external environment or one's own condition, outbursts of anger, nightmares, hallucinations, psychoses, abnormal behaviour, and other undesirable behaviours may occur. If such symptoms occur, contact a doctor immediately.

The above-mentioned symptoms are more likely to occur in children and elderly patients.

Duration of treatment

The duration of treatment is limited (should not exceed 8–12 weeks), and the dose should be gradually reduced under medical supervision. During discontinuation of the medicine, a rebound phenomenon may occur (see section 3, "Discontinuing Lexotan").

Alcohol consumption or use of medicines that depress central nervous system function

During treatment with Lexotan, alcohol should not be consumed and medicines that depress central nervous system function should not be taken.

Alcohol may intensify the effect of Lexotan and cause severe sedation, as well as respiratory or circulatory depression, which may lead to coma or death.

Tolerance

Repeated administration of Lexotan over a prolonged period may lead to reduced effectiveness of the medicine.

During benzodiazepine treatment, if the medicine used is replaced with a benzodiazepine having a significantly shorter half-life, withdrawal symptoms may develop.

Benzodiazepines should not be used as the sole treatment for depression or anxiety states associated with depression (in such conditions, suicidal tendencies may be increased).

Benzodiazepines should not be used as first-line treatment for psychotic disorders.

Due to the muscle-relaxant effect of the medicine, there is a risk of falls and hip fractures, especially in elderly patients who get up at night.

History of alcohol, drug or substance abuse

The medicine should be used with particular caution and strictly according to the doctor's instructions.

Medication dependence

Taking medicines from the benzodiazepine group, including Lexotan, or similarly acting medicines, may lead to the development of both physical and psychological dependence. The risk of dependence increases with dose and duration of treatment. The risk is also higher in patients with a history of alcohol, drug or substance abuse, and in patients with personality disorders.

Warnings regarding specific patient groups

Particular care should be taken in patients with chronic respiratory insufficiency due to the risk of respiratory disturbances.

Extreme caution should be exercised in patients with mild or moderate hepatic impairment.

Benzodiazepines should not be administered to children without careful assessment of the justification for their use; treatment duration should be as short as possible, and the dose should be individually adjusted for each patient.

Elderly patients should receive a reduced dose.

Pregnancy and breastfeeding

Before using any medicine, consult a doctor or pharmacist.

Pregnancy

The safety of bromazepam use in pregnant women has not been definitively established. Although there are no clinical data indicating significant congenital malformations in the fetus due to benzodiazepine use during the first trimester of pregnancy, some epidemiological studies have shown an increased risk of oral clefts.

Therefore, bromazepam should not be used during pregnancy unless strictly indicated in exceptional circumstances and with strict adherence to the dosing regimen.

Patients should consult a doctor about discontinuing treatment if they are planning to become pregnant or suspect they may be pregnant.

Administration of bromazepam during the third trimester of pregnancy and during childbirth is permitted only in cases of absolute necessity, as adverse effects in newborns may be expected, such as hypothermia (lowered body temperature), reduced muscle tone leading to sucking difficulties (resulting in poor weight gain), and moderate respiratory depression or apnoea. Additionally, withdrawal symptoms in the newborn, manifesting as excessive irritability, restlessness, and tremors, have been observed.

In infants whose mothers took benzodiazepines long-term during the final stages of pregnancy, physical dependence on the drug and risk of withdrawal symptoms after birth may occur.

Breastfeeding

Benzodiazepines pass into breast milk; therefore, women who are breastfeeding should not use Lexotan.

Driving and operating machinery

Do not drive or operate machinery, as Lexotan may cause excessive sedation and amnesia, impair concentration and muscle function. In case of sleep deprivation, the likelihood of reduced alertness may increase. This effect may be particularly intensified if the patient has also consumed alcohol.

Lexotan and other medicines

Inform the doctor about all medicines currently or recently taken, as well as any medicines the patient intends to use.

Concomitant use of Lexotan with any medicines that depress the central nervous system (e.g. antidepressants, hypnotics, opioid analgesics, neuroleptics, anxiolytics and sedatives, anticonvulsants, sedative antihistamines, anaesthetics) and alcohol may enhance the sedative effect of the medicine and increase its depressive effects on the respiratory and circulatory systems.

When opioid analgesics are used concomitantly, a state of euphoria may occur, increasing the risk of psychological dependence.

Substances that inhibit the activity of certain liver enzymes may affect benzodiazepines metabolized by these enzymes. Concomitant administration of Lexotan with cimetidine, fluvoxamine, or (probably) propranolol may result in stronger or prolonged effects.

Lexotan contains monohydrate lactose. If the patient has previously been diagnosed with intolerance to certain sugars, the patient should consult a doctor before taking Lexotan.

3. How to use Lexotan

This medicine should always be used as directed by the physician. In case of doubt, consult your
doctor.
Lexotan is available in 3 mg and 6 mg doses.
In all cases, Lexotan should be used under medical supervision.
Typical dosage
Average doses for outpatients: 1.5 mg to 3 mg up to three times daily.
Severe cases, especially in hospital treatment: 6 mg to 12 mg two or three times daily.
The physician should treat these dosage recommendations as general guidelines and adjust the dose
individually for each patient. Outpatient treatment should begin with low doses, gradually increasing
them to the optimal level. Treatment should be as short as possible.
Patients should visit their doctor regularly to evaluate the need for continued medication, especially
when disease symptoms are no longer present. Total treatment duration should not exceed 8 to 12
weeks, including the tapering-off period.
In some cases, therapy may last longer, provided a specialist assessment of the patient's condition
has been performed by the physician.
Elderly patients and patients with impaired liver function require lower doses.
If the effect of Lexotan seems too strong or too weak, consult your doctor.
Taking more than the recommended dose of Lexotan
If an overdose is taken, contact your doctor immediately.
The doctor will decide on further management.
Common symptoms of benzodiazepine overdose include: drowsiness, impaired coordination,
speech disturbances, and nystagmus.
Overdose with Lexotan is rarely life-threatening when the drug is taken alone. However, it may lead
to loss of reflexes, respiratory arrest, hypotension, cardiorespiratory depression, and coma. Coma, if
it occurs, usually lasts several hours but may recur and worsen, especially in elderly individuals.
Symptoms of respiratory depression are more severe in patients with pre-existing respiratory
diseases.
Benzodiazepines enhance the effects of other central nervous system depressants (including alcohol).
Missed dose of Lexotan
Do not take a double dose to make up for a missed dose.
Stopping Lexotan treatment
If physical dependence has developed, withdrawal symptoms (withdrawal syndrome) may occur
after discontinuation of treatment.
These may include: headache, diarrhea, muscle pain, increased anxiety, tension, restlessness,
disorientation, and irritability. In severe cases, the following symptoms may occur:
distorted perception of surroundings (derealization), disturbances in self-awareness
(depersonalization), hypersensitivity to sound, numbness and tingling in the limbs, sensitivity to
light, noise, and touch, hallucinations, or seizures.
After stopping the medication, "rebound anxiety" may occur—a transient syndrome in which the
symptoms that led to the use of Lexotan return in an intensified form. Other reactions may also
occur, such as: mood changes, anxiety, sleep disturbances, and restlessness.
Because the risk of withdrawal syndrome and "rebound" phenomena is greater with abrupt
discontinuation of treatment, gradual reduction of the Lexotan dose is recommended.
If you have any further questions about the use of this medicine, consult your doctor.

4. Possible adverse reactions

Like all medicines, Lexotan may cause adverse reactions, although not everyone experiences them.
The adverse reactions listed below occurred at an unknown frequency (cannot be estimated from the available data):

• hypersensitivity (allergy), anaphylactic shock, angioedema
• confusion, disorientation, emotional disturbances and mood disturbances – mainly at the beginning of treatment and usually subsiding during treatment
• libido disorders
• drug dependence, drug abuse, withdrawal syndrome
• depression
• paradoxical reactions such as anxiety, restlessness, irritability, aggression, delusions, anger, nightmares, hallucinations, psychosis, unusual behaviour, nervousness, anxiety, unusual dreams, excessive activity and other behavioural disturbances – these types of reactions are more likely in children and elderly patients
• anterograde amnesia
• memory impairment
• drowsiness, headache, dizziness, reduced alertness, coordination problems and balance disturbances – mainly at the beginning of treatment and usually subsiding during treatment
• double vision – mainly at the beginning of treatment and usually subsiding during treatment
• heart failure, including cardiac arrest
• reduced depth and frequency of breathing
• nausea, vomiting – mainly at the beginning of treatment and usually subsiding during treatment
• constipation
• rash, itching, urticaria
• muscle weakness – mainly at the beginning of treatment and usually subsiding during treatment
• urinary retention
• fatigue – mainly at the beginning of treatment and usually subsiding during treatment
• falls, fractures – risk is increased in patients concurrently using sedatives (including alcoholic beverages) and in elderly patients.

Dependence:
Long-term use of the medicine (even at therapeutic doses) may lead to the development of psychological and physical dependence. Discontinuation of treatment may result in withdrawal symptoms or rebound anxiety (worsening of disease symptoms – see "Discontinuation of Lexotan treatment").
Cases of benzodiazepine abuse have been reported.

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor, pharmacist or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Reporting adverse reactions helps to increase the knowledge about the safety of this medicine.

5. How to store Lexotan

Keep this medicine out of sight and reach of children.
Do not store at temperatures above 30°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Proper disposal helps protect the environment.

6. Contents of the pack and other information

What Lexotan contains

• The active substance is bromazepam (Bromazepamum). 1 tablet contains 3 mg of bromazepam.
• Other ingredients are: microcrystalline cellulose, magnesium stearate, talc, monohydrate lactose (94.4 mg per tablet), red iron oxide.

What Lexotan looks like and contents of the pack
Lexotan is in the form of tablets.
The pack contains 30 tablets in blisters, placed in a cardboard box.
For more detailed information, please contact the marketing authorisation holder or the parallel importer.
Marketing authorisation holder in Austria, country of export:
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald, Germany
Manufacturer:
Delpharm Milano S.r.l.
Via Carnevale, 1
20090, Segrate (MI)
Italy
Parallel importer:
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Repackaged in:
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Austrian marketing authorisation number, country of export: 16.224
Parallel import authorisation number: 13/22